mtm laboratories raises EUR 22 million in Series C financing
mtm laboratories announced that it has raised EUR22 million in a Series C financing from a consortium of existing and new investors. Proceeds from this financing will enable the Company to fund the clinical development and commercialization of its proprietary diagnostic and screening devices in the field of cervical cancer.
The funding round was led by HBM BioVentures and HBM BioCapital, with a consortium which includes Heidelberg Innovation and Wellington Partners together with the new investors Nexus Medical Partners (Boston) and SwissFirst Bank (Zurich).
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.